The salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than oral montelukast 10 mg od as a first line therapy in mild and moderate asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001
The effects of fluticasone propionate/salmeterole 50/100 μg bid in children with asthma versus beclometasone propionate 200 μg BD and fluticasone propionate 100 μg bid dry powder inhaletors Source: Eur Respir J 2004; 24: Suppl. 48, 378s Year: 2004
Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 346s Year: 2004
12 weeks comparing salmeterol/fluticasone proprionate (SFC, 50/100 microg b.d. diskus) versus fluticasone proprionate (FP, 250 microg b.i. diskus) as first-line regular asthma treatment Source: Eur Respir J 2003; 22: Suppl. 45, 236s Year: 2003
Ciclesonide 160 μg once daily compared with fluticasone propionate 250 μg twice daily in maintenance therapy of patients with stable asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Comparison of mometasone furoate dry powder inhaler 400 mcg once daily in the evening with fluticasone propionate metered dose inhaler 250 mcg twice daily in asthma patients previously maintained on fluticasone propionate Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
The salmeterol/fluticasone propionate combination 50/100 μg b.i.d is effective as initial maintenance therapy in mild and moderate asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Ciclesonide 80 μg or 160 μg once daily is comparable to fluticasone propionate 88 μg twice daily in the treatment of asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005
Superior efficacy of the salmeterol/fluticasone 50/100 mcg combination compared to fluticasone 200 mcg in children with uncontrolled asthma – the VIAPAED trial Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008
Ciclesonide once daily (80 mg/d, 160 mg/d) versus fluticasone propionate twice daily (250 mg/d) in the treatment of patients with persistent asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010
Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
Low-dose (100 μg, b.i.d. ) inhaled fluticasone propionate (FP) is as effective as high-dose (500 μg, b.i.d. ) in mild symptomatic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Evaluation of long-term safety, growth and efficacy of fluticasone propionate 100mcg bd compared with sodium cromoglycate 5mg qds in asthmatic children aged 12-47 months Source: Eur Respir J 2002; 20: Suppl. 38, 219s Year: 2002
Comparable efficacy of ciclesonide 160 μg once daily and budesonide 200 μg twice daily in patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005
Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Comparison of once-daily ciclesonide 160 μg versus twice-daily fluticasone propionate 88 μg in children with moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 711s Year: 2006
Fluticasone propionate 100μg bd (FP100) has significantly less effect than budesonide 200μg bd (BUD200) on childhood growth over 1 year of treatment in asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 219s Year: 2002
Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Comparison of ciclesonide once daily (80 μg/d, 160 μg/d) and fluticasone propionate twice daily (176 μg/d) in the treatment of children with persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 457s Year: 2007
Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005